On 12 October 2026 Singapore’s Health Sciences Authority (HSA) announced a package of measures to accelerate innovative health products to market through stronger international cooperation and streamlined regulatory mechanisms. Buried in the same announcement is a milestone with wider implications: HSA has become the first national regulator recognised by the World Health Organization at maturity level 4 (ML4) for medical device regulation.
Official source
HSA announcement: Strengthening local and global partnerships to accelerate healthcare innovations
1. Three regulatory innovation measures
An HSA-MHRA Regulatory Innovation Corridor
HSA and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) are establishing a Regulatory Innovation Corridor to support the development of innovative health products. Its focus areas are the application of AI in healthcare, and the regulation of innovative product development and clinical trials. The two regulators will communicate in parallel so that companies can plan registration pathways earlier, avoid duplicated work and shorten the path from development to market.
A single entry point for clinical research and regulatory dialogue
Enterprise Singapore, the Economic Development Board (EDB), HSA and the Singapore Clinical Research Institute (SCRI) will jointly coordinate a single entry point for clinical research and regulatory communication. Expected in early 2027, it is intended to give companies more coordinated regulatory support instead of separate conversations with each agency.
An ACE-HSA Priority Track from November 2026
From November 2026, HSA and the Agency for Care Effectiveness (ACE) will operate a priority track for selected innovative products, allowing the regulatory evaluation and the health technology assessment (HTA) to run in parallel rather than sequentially – directly shortening the total time to a funding and access decision.
2. WHO recognition at the highest maturity level
The announcement states that in 2026 HSA became the first national regulatory authority worldwide to achieve WHO maturity level 4 (ML4) for medical device regulation – the highest level in WHO’s Global Benchmarking Tool, denoting a regulatory system that is stable, well-functioning and continuously improving. HSA also holds WHO’s highest recognition for medicines regulation and WHO Stringent Regulatory Authority status for high-risk IVDs.
Singapore has additionally joined the Access Consortium, working alongside Australia, Canada, Switzerland and the United Kingdom to share assessment experience and deepen regulatory cooperation.
3. Towards an integrated healthcare regulatory system
Singapore intends to consolidate healthcare regulatory functions further, with HSA taking on a broader, more integrated role spanning health products, healthcare services, health information, health research and the regulation of healthcare professionals. For industry, the stated goal is a more coordinated and predictable regulatory environment with fewer interfaces to navigate.
4. What this means for device manufacturers
Nothing in the announcement changes the technical requirements for device registration. The significance is strategic rather than documentary:
- Singapore’s standing as a reference regulator is strengthened, which reinforces the value of an HSA listing when using reliance routes into Malaysia, Thailand and other ASEAN markets;
- Companies developing AI-based devices, SaMD and other innovative products should watch the HSA-MHRA corridor and the ACE-HSA Priority Track as potential accelerators for both approval and reimbursement;
- For ASEAN portfolio planning, Singapore increasingly functions as the regulatory anchor market: one English-language filing, a predictable timeline, and now the strongest external validation of any regulator in the region.
GRZAN’s wholly owned Singapore entity, GRZAN GROUP PTE. LTD., provides local Registrant services, HSA registration and authorised representative support, and coordinates reliance filings into Malaysia and Thailand.
Summarised from HSA’s announcement of 12 October 2026. Implementation dates and scope for the corridor, the single entry point and the priority track are those announced by HSA and may be refined in subsequent guidance.